Clinical trials: Methylphenidate
Healthy
A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers
The purpose of the study is to evaluate the pharmacokinetics and safety of 3 single doses of Methylphenidate HCl in healthy Japanese adult male volunteers.
- Trial name
- NCT01202734
- Testing
- Methylphenidate HCl
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV
Attention-Deficit Hyperactivity Disorder
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
- Trial name
- NCT01323192
- Testing
- JNS001
- Where
- 30 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Janssen Pharmaceutical K.K.
Attention Deficit/Hyperactivity Disorder
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P02 (NCT05721235)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 123 people
- Sponsor
- Corium, Inc.
Attention Deficit Disorder With Hyperactivity
Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients
The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.
- Trial name
- NCT00664703
- Testing
- Lobeline sulfate, Methylphenidate HCl
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yaupon Therapeutics
Depressive Disorder, Major
CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.
The purpose of this study is to evaluate the effects of the addition of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) or placebo in adult outpatients with Major Depressive Disorder who are…
- Trial name
- NCT00246233
- Testing
- methylphenidate
- Volunteers
- 145 people
- Sponsor
- Janssen-Ortho Inc., Canada
Attention Deficit Disorder With Hyperactivity
Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged…
- Trial name
- NCT00151996
- Testing
- Methylphenidate + SPD503 (Guanfacine hydrochloride), Amphetamine + SPD503
- Volunteers
- 75 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the…
- Trial name
- NCT00246207
- Testing
- CONCERTA (OROS methylphenidate hydrochloride)
- Volunteers
- 32 people
- Sponsor
- Janssen-Ortho Inc., Canada
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.